DCM
QNCX icon

DAFNA Capital Management’s Quince Therapeutics QNCX Stock Holding History

DAFNA Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-327
Closed -$2.78M – 92
2019
Q2 		$2.78M Buy
+327
New +$1.95M 1.05% 28

Other funds holding QNCX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAFNA Capital Management's QNCX Position: Q3 2019 in Review

DAFNA Capital Management sold out of Quince Therapeutics (QNCX) in Q3 2019, closing a stake of 327 shares — an estimated $2.78M sold.

DAFNA Capital Management first reported a position in QNCX in Q2 2019 and held it in 1 quarter. The position peaked at $2.78M in Q2 2019. 39 funds tracked by Wall St. Rank hold QNCX as of Q3 2019.

  • DAFNA Capital Management reported no remaining Quince Therapeutics position as of Q3 2019 after selling out during the quarter.
  • DAFNA Capital Management sold 327 Quince Therapeutics shares in Q3 2019, an estimated $2.78M.
  • DAFNA Capital Management first reported a position in Quince Therapeutics in Q2 2019 and held it in 1 quarter.
  • DAFNA Capital Management's Quince Therapeutics position peaked at $2.78M in Q2 2019.
  • 39 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2019.

Based on DAFNA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.